IMDRF Releases Consultation on Guidance for Control of Products and Services Obtained from Suppliers

Source

Issuing body: IMDRF
Original date: 6 May 2026
Published on this site: 8 July 2026, 09:00
Original link: https://www.imdrf.org/consultations/guidance-control-products-and-services-obtained-suppliers

The IMDRF Quality Management System Working Group has released a proposed document on the control of products and services obtained from suppliers for public consultation, highlighting the need for medical device companies to focus on outsourcing, critical suppliers and quality management system evidence.

Full Translation of Core Content

The IMDRF consultation page states that the Quality Management System Working Group has published a proposed document on the control of products and services obtained from suppliers and is seeking comments. Supplier control is an important part of a medical device quality management system. It covers outsourced design, critical components, sterilization services, testing services, software services, logistics services and other external resources that may affect product safety and performance.

The document reflects continued attention to supply chain control at the level of international regulatory coordination. Medical device companies cannot focus only on whether final product testing is passed. They also need to demonstrate that critical suppliers, outsourced processes and service providers are under control. Supplier selection, quality agreements, change notification, acceptance criteria, periodic evaluation and risk classification are all matters that may be reviewed.

In multi-country registration projects, weak supplier control evidence may affect technical documentation, quality management system audits, notified body review and post-market change management.

AIMEILI Regulatory Interpretation

AIMEILI Regulatory Affairs considers that updates relating to GMP, supplier control and data integrity point to regulators' continuing focus on the credibility of evidence. Medical device registration is not simply a matter of submitting test reports, quality management system certificates and technical documents. Regulators will increasingly examine the manufacturing processes, outsourcing controls, supply chain changes, raw data and record consistency behind those materials.

For companies, third-party testing, sterilization, software outsourcing, critical components, clinical data, performance verification and quality management system records all need to be traceable. If supplier changes are not assessed, test data lack raw records, or the manufacturing address, model and specification, process flow and quality management system scope in the registration materials are inconsistent, problems may emerge during review, quality system inspections or post-market investigations, even if individual documents appear complete.

AIMEILI recommends that companies conduct a documentation credibility review before overseas registration: verify whether certificates, test reports, raw records, supplier agreements, change records, quality agreements and technical documents are consistent with each other. For companies preparing to enter markets such as Korea, the United States, the European Union and Canada, quality management system evidence should be developed in parallel with registration materials, rather than explained on an ad hoc basis after regulators raise questions.

Business Impact

In multi-country registration, regulators and notified bodies are paying increasing attention to whether companies can control supply chain risks. If critical suppliers, outsourced processes, change notification, purchasing verification or quality agreements are missing, risks may arise in quality system audits or technical documentation review even where product test results are satisfactory.

Compliance Actions for Manufacturers

• Confirm whether this update affects existing registration pathways, certificate maintenance or post-market obligations.
• Verify the technical documentation, labels and instructions for use, quality management system and local responsible entity arrangements for the target country.
• Establish change impact assessments and records for tracking regulatory updates for marketed products.
• Where necessary, archive the official original text, the Chinese-language interpretation and internal action items to support future audits and project reviews.

Content Review and Scope

Content author: AIMEILI Regulatory Editorial Department
Professional review: AIMEILI Medical Device International Registration Project Team
Source principle: Priority is given to official regulatory authorities, international organizations, standards organizations and publicly available regulatory materials; industry media and project experience are used only as supporting judgment.
Scope: This article is intended for preliminary understanding, documentation preparation and project planning. It does not replace the formal requirements of target-country regulators, testing conclusions or legal advice.